Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ...

Now, researchers in a lab at the University of Minnesota, using a drug called CD200AR-L, have developed their own vaccine to ...

The authors have undertaken a useful study to update an existing niche model of highly pathogenic avian influenza. However, there are issues regarding the conceptualisation of the ecological niche of ...

Theralase validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the ...

Theralase® validates previous University of Manitoba research by demonstrating that RuvidarTM is safe and effective in the treatment of the Herpes Simplex Virus in an animal model. TORONTO, ON / ACCES ...

The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...

Scientists at Sanaria and Seattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Pliant Therapeutics paused its phase 2b/3 trial of bexotegrast for idiopathic pulmonary fibrosis due to DSMB recommendations.

Bengaluru: Bharat Biotech group company Biovet, an innovative animal health vaccine producer based in Mallur, Karnataka, has ...

Bharat Biotech's group company, Biovet, has launched the world's first-ever Lumpy Skin Disease (LSD) vaccine, Biolumpivaxin, ...

More than 90% of Omvoh-treated patients who were in clinical remission at one year sustained it with two years of continuous treatment Omvoh works to reduce inflammation within the gastrointestinal ...